The site at Ulverston currently belongs to GlaxoSmithKline (GSK), which is winding down its ... area as a "nationally-advanced manufacturing location". The proposals include "flexible office ...

It is believed about 200 roles will be cut at the facility in Barnard Castle, County Durham, in October 2025. The team ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...

Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...

GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

Partnership is integral to GSK. Bringing people together is the best way to innovate and deliver products that transform the standard of care and improve lives. Over half of GSK’s clinical ...

GSK has revealed updated results from its phase ... In the latest results from the 457-patient B-Clear study, published in the New England Journal of Medicine, bepirovirsen at a dose of 300 ...

On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...